ArticlebioRxiv : the preprint server for biology2026
Morphomechanically-Informed Spatial Curvature Sequencing in Prostate Cancer.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Morphological changes in prostate glands, assessed by Gleason grading, remain the gold standard for diagnosing prostate cancer, yet molecular biomarkers associated with gland shape are not well understood. Here, we introduce CurvSeq, a mechanomorphology-informed framework for spatial sequencing data, and CurvSee, its complementary version for proteomic and imaging datasets. These methods integrate gland boundary curvature, pocket architecture, microenvironmental composition, and molecular profiles to study morphomechanical relationships in prostate adenocarcinoma. Using five independent spatial transcriptomic and multiplexed imaging datasets, we segmented individual prostate glands, extracted gland contours, quantified local curvature and pocket-like concavities, and projected these features onto spatially resolved gene and protein measurements. In Xenium data, CurvSeq distinguished benign and GG1 glands, identifying cancer-associated genes such as PCA3 and AMACR in GG1 glands and basal, basement membrane, and mechanotransduction-associated programs in benign glands. In Visium data, a diffusion-based morphomechanical score ordered benign glands by area, circularity, pocket number, smooth muscle abundance, immune-cell proximity, and remodeling-associated genes including MMP7. In GG4 glands, CurvSeq identified neuroendocrine-like boundary regions associated with MMP7 expression, COL1A1-rich adjacent stroma, and immune-cell accumulation. Finally, CurvSee extended this framework to multiplexed protein imaging, where combined morphology and protein-expression features distinguished Gleason-associated gland states. Together, CurvSeq and CurvSee provide a quantitative framework for linking gland architecture, local microenvironment, and molecular state, showing that prostate gland morphology can be integrated with spatial omics to identify morphomechanical niches associated with cancer progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.